ReviewBiochemistry and biophysics reports2025
Unlocking nature's potential: Soursop in the battle against resistant acute myeloid leukemia.
Review in Biochemistry and biophysics reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute Myeloid Leukemia (AML) represents the predominant form of blood cancer in adults and ranks as the second most prevalent in pediatric populations. The disease is heterogeneous, characterized by proliferation and self-renewal, originating in the bone marrow and potentially metastasizing to various body regions. AML arises from a hematopoietic abnormality characterized by the accumulation of myeloblasts, which are immature myeloid cells. Genetic disorders, a medical history of bone marrow disorders, and chemoradiation can lead to genetic mutations that impact hematopoiesis. Leukemic stem cells (LSC) exhibit biological similarities to normal hematopoietic stem cells (HSC), yet they lose the capacity to differentiate progenitor blast cells into mature cells. As a result, progenitor blast cells remain inactive in the G
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.